2016 Volume 42 Issue 12 Pages 834-838
We report the case of a patient with oxaliplatin-induced thrombocytopenia during chemotherapy for colorectal cancer. In this patient, the administration of oxaliplatin was discontinued due to an allergic reaction during the 16th course of chemotherapy with oxaliplatin. The 17th or subsequent courses of chemotherapy were performed without changing the regimen, leading to drug-induced thrombocytopenia. Although oxaliplatin-induced thrombocytopenia has been reported as an adverse reaction, its incidence is low, and other factors causing thrombocytopenia are present, making diagnosis difficult. In the case of thrombocytopenia complicated with an allergic reaction to oxaliplatin, we consider the immunological mechanism, and measurement of platelet associated immunoglobulinG can be performed, too. When chemotherapy-related allergic symptoms are mild, administration is continued in many cases, considering the advantages of the treatment. However, the possibility that readministration may induce serious adverse reactions must be considered.
